A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

Recruiting

Phase 2

IPN10200A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

Sponsor:

Ipsen

Code:

NCT06625060

Conditions

Episodic Migraine

Chronic Migraine

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

IPN10200

Placebo

IPN10200 dose A

IPN10200 dose B

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-30. This information was provided to ClinicalTrials.gov by Ipsen on 2025-08-28.